Dutch Organization for Health Research and Development awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program

18

Feb 2022

The Healthcare Evaluation and Appropriate Use (Zorgevaluatie en Gepast Gebruik ZE&GG) is a joint initiative of all parties of the Outline Agreement on Medical Specialist Care (HLA-MSZ) (healthcare providers, health insurers, patients, and Government) with the objective to implement appropriate use of specialist medical care.

The basic principle of the Healthcare Evaluation and Appropriate Use Program is that the health care assessment will become a part of the regular care processes and care provision and will lead to its appropriate use. The program was initiated in 2019 and will continue until 2024 with a total budget of €46,953,000.

In November 2020, all parties approved the first plan containing ten research questions for which care evaluation should be carried out. The Dutch Organization for Health Research and Development (ZonMw) assessed the subsidy applications.

In January 2022, the following eight projects have been awarded the subsidy:

  • Effectiveness of personalized care after treatment for non-metastatic breast cancer based on the risk of recurrence, personal needs, and risk of (late) health effects (the NABOR study); 
  • Optimized pharmacotherapy with improved continuity of care in hospitalized older people to examine whether medication-related readmissions to the hospital can be prevented in older people with polypharmacy (the simultaneous use of several different medicines) (the LIMONCELLO study);
  • Impact of preoperative structured multidisciplinary team consultation on the outcomes of treatment of patients with a high risk of complications, including the number of complications, improvement of the patient's life, increased cost-effectiveness and functional outcomes (the PREPARATION study);
  • Impact of a comprehensive geriatric assessment, including advance care planning, in acutely hospitalized vulnerable elderly patients with cognitive impairments (the GOAL study);
  • Comparison of surgical treatment (robot-assisted radical prostatectomy) with external irradiation with hormone therapy in the extensive form of prostate cancer without metastases with the assessment of the patient's quality of life, cost-effectiveness, and progression-free survival (the RECOVER study);
  • Cost-effectiveness and clinical outcomes of a CT-driven diagnostics and therapy compared to standard care in patients with suspected coronary artery disease (the CLEAR CAD study);
  • Use of statins in frail older patients with ischemic stroke or transient ischemic attack (the SAFEST study);
  • A multicenter randomized controlled trial of narrowband UVB light therapy versus optimal topical therapy (ointment therapy) in adults with atopic eczema (the UPDATE study).

The full details in Dutch can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

28

Nov 2022

The new version of the classification of procedure codes (CCAM v.71), applicable from December 03, 2022, was published in France. Several changes were introduced, including the creation of four new codes related to ENT, pulmonary and airways, and interventional radiology areas. Also, the modification of tariffs for 50 dental procedure codes will enter into force on January 01, 2023.

Read more

22

Nov 2022

On October 27, 2022, the BfArM (Federal Institute for Drugs and Medical Devices) published the final version of the 2023 OPS procedure coding classification. The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification), forms the basis for the reimbursement systems in outpatient and inpatient care in Germany.

Read more

15

Nov 2022

On November 3, 2022, the decision of the National Union of Health Insurance Funds relating to the update of the CCAM Nomenclature of procedure codes was published in the Official Journal of the French Republic. Four new procedure codes were introduced. The codes relate to the procedures of implantation and removal of the bone conduction hearing aid and destruction of bronchopulmonary tumors by radiofrequency.

Read more

11

Nov 2022

MedTech-related health technology assessments from NIHR in October 2022
In October 2022, the National Institute for Health and Care Research (NIHR) in England released one MedTech-related report in its Health Technology Assessment (HTA) Journal, which concerned photodynamic versus white-light-guided resection of non-muscle-invasive bladder cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

10

Nov 2022

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in October 2022. Fourteen recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular, neurovascular, orthopedic, and ENT devices, as well as medical aids.

Read more